Acute myeloid leukemia, FLT3 internal tandem duplication
MONDO:0100415Any acute myeloid leukemia that has the chromosomal anomaly FLT3 internal tandem duplication. (A genetic abnormality that arises from duplications of the juxtamembrane portion of the gene and results in constitutive activation of the FLT3 receptor tyrosine kinase protein in early hematopoietic progenitor cells. It is associated with acute myelogenous leukemia where it appears to correlate with a poor prognosis.)
Also known as: AML, Activating FLT3-ITD Gene Mutation, AML, Activating FLT3-ITD Mutation, AML, FLT3 ITD, AML, FLT3 internal tandem duplication, AML, FLT3-ITD, AML, FLT3-ITD Activating Mutation, AML, FLT3-ITD Mutation, AML, FLT3/ITD Mutation
3109 clinical trials for this condition and its sub-types, 18 tagged with Acute myeloid leukemia, FLT3 internal tandem duplication itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug combo aims to outsmart aggressive leukemia
Disease control CompletedThis trial tests whether adding the targeted drug ponatinib to standard chemotherapy (cytarabine) can help prevent relapse in adults with a specific, high-risk genetic form of acute myeloid leukemia (FLT3-ITD AML) who are already in first remission. The study includes two age gro…
Phase 1/2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug shows promise in leukemia battle
Disease control CompletedThis study tested a new drug, crenolanib, against the standard drug midostaurin in adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). All 214 participants received standard chemotherapy and, if eligible, a bone marrow transplant, plus one of the two…
Phase 3 • Sponsor: Arog Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo targets Leukemia's genetic weakness
Disease control CompletedThis study tested whether adding the drug crenolanib to standard chemotherapy helps adults up to age 75 with a hard-to-treat form of acute myeloid leukemia (AML) that has a specific genetic change (FLT3 mutation). Participants received either crenolanib or a placebo alongside che…
Phase 3 • Sponsor: Arog Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise for aggressive blood cancer
Disease control CompletedThis study tested a drug called gilteritinib (Xospata) alongside standard chemotherapy in 97 people newly diagnosed with acute myeloid leukemia (AML), especially those with a FLT3 gene mutation. The first part aimed to find the safest dose, and the second part measured how many p…
Phase 1/2 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC